Obesity evidence dossier
Oral Wegovy (semaglutide 25 mg)
The practical appeal is oral convenience, although administration routine and gastrointestinal tolerability still matter.
Total weight loss
13.6%
OASIS 4 · 25 mg · week 64 · Includes treatment stops
Placebo-adjusted
11.2%
Difference from placebo in the same study when reported.
Study context
Oral GLP-1 receptor agonist/Adults with obesity or overweight, without diabetes/307 participants across the study/64-week endpoint
Baseline: See the source for enrollment criteria
Ranked result & calculation
OASIS 4 · 25 mg · 64 weeks
Adults with obesity or overweight, without diabetes. 307 participants across the study (not this dose arm alone).
Includes treatment stops. Treatment-policy results estimate outcomes regardless of stopping treatment.
- Average weight loss
- 13.6%
- Placebo group
- 2.4% loss
- Beyond placebo
- 11.2 percentage points (arm subtraction)
- Stopped due to adverse events
- Not verified for this result
Score: 70% × 55.8 total-loss points + 30% × 55.3 beyond-placebo points = 56/100, rounded. Conversion scales
Alternative analysis assuming continued treatment: 16.6% total loss. This is not the result used for the headline score. Alternative analysis source ↗
Novo Nordisk, OASIS 4 ↗Phase 3 · Sponsor disclosure · Reviewed 2026-09-21
Evidence
Benchmark read
OASIS 4: Includes treatment stops.
Diabetes data
Oral semaglutide diabetes data should be compared separately from obesity-dose OASIS data.
Safety
Side effects and cautions
Discontinuation read
Adverse-event discontinuation has not been verified for this result.
Common side effects
Expected GLP-1 adverse reactions include nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, and reflux.
Main cautions
Cautions align with semaglutide class labeling; oral dosing routine can affect real-world adherence.
Upcoming catalyst
What to watch next
Commercial uptake versus injectable Wegovy, Zepbound, and oral orforglipron.
Linked clinical trials
Trials in the saddl3 obesity snapshot
Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.